This inventor holds 4 USPTO granted patents and 1 EPO patent. Top assignee: Santen Pharmaceutical Co., Ltd.. Active years: 2015-2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015-2018
Title: Innovations by Hiroshi Deguchi
Introduction
Hiroshi Deguchi is a notable inventor based in Ikoma, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with improved stability and reduced side effects. With a total of 4 patents to his name, his work continues to impact the industry positively.
Latest Patents
Deguchi's latest patents include the development of 2-[[[2-[(Hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate and its crystal forms. In the course of developing this compound, he encountered several challenges, including difficulties in recrystallization and issues with storage stability. His research led to the discovery that the benzenesulfonate form of the compound does not decompose under various conditions, demonstrating excellent storage stability. Additionally, he developed methods to selectively produce two crystal forms of the compound, which do not cause mineral deposition in the stomach upon repeated oral administration.
Career Highlights
Hiroshi Deguchi has been instrumental in advancing pharmaceutical formulations at Santen Pharmaceutical Co., Ltd. His innovative approaches have not only addressed critical issues in drug stability but have also paved the way for safer medication options for patients.
Collaborations
Deguchi has collaborated with Masashi Niwa, contributing to the successful development of their patented compounds. Their teamwork exemplifies the importance of collaboration in the field of pharmaceutical research.
Conclusion
Hiroshi Deguchi's work exemplifies the spirit of innovation in the pharmaceutical industry. His contributions have led to significant advancements in drug stability and safety, showcasing the impact of dedicated research and collaboration.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
